Summary. Two chemoattractants. the peptide N-formyl-metleu-phe (FMLP), and the ether phospholipid, platelet activating factor (PAF), each stimulate a variety of in vitro responses in polymorphonuclear leucocytes (PMN). Because often more than one inflammatory mediator is active during inflammation, we determined the effect on PMN of sequential stimulation with these two agents. Before FMLP stimulation, human PMN were exposed to PAF, at concentrations which gave little or no response when administered alone. PAF enhanced FW-elicited superoxide release in a dose-dependent fashion. Likewise, release of granular lysozyme from the cells was increased in PAF treated cells. Similar treatment with other phospholipids, including the lyso derivation of PAF, failed to produce these effects. Incubation with nordihydroguaiaretic acid, an inhibitor of arachidonic acid metabolism, had little effect on the enhancement of lysozyme release by PAF. To determine if enhancing effects by PAF might occur also in vivo, we studied rabbits receiving PAF and/or FMLP intravenously. When rabbits received 0.01 pg PAF (a dose which does not elicit the sustained neutropenia observed with higher doses of PAF) followed by 0.05 pg FMLP the absolute granulocyte count (AGC) dropped at 1 min (46 f 11% of original value), and continued to fall (24 f 12% at 10 min). Controls, treated with the suspending fluid for PAF, and then 0.05 pg FMLP, had a similar 1 min AGC value, but at 10 min AGC returned to 65f6.1% (P<O.OOl for comparison of 10 min values). Thus PAE pretreatment enhanced FMLP-elicited granulocytopenia in viva Study of in vitro human PMN aggregation revealed that, at certain relative concentrations of PAF and F W , aggregation was enhanced. These studies show that both in vitro and in vivo responses of FW-stimulated PMN may be exaggerated by pre-exposure to PAP.
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During inflammation, the polymorphonuclear leucocyte (PMN) is exposed to a multitude of bioactive substances. Among these substances are likely the chemoattractive formylated peptides, similar to N-formyl-met-leu-phe (FMLP), which are released by microorganisms (SchiRmann et aJ, 1975a, b) . Also important are a variety of lipid mediators including the platelet activating factor (PAF). l-O-alkyl-2-acetyl-3-phosphorylcholine (Godfroid et aJ, 1980 which is released from various cells including the PMN themselves (Betz & Henson, 1980; Clark et aJ, 1980 : Sanchez-Crespo et aJ, 1980 Goetzlet aJ. 1980) . The in vivo responses of PMN, however, are likely modulated by these agents acting in concert or in sequential fashion. We had observed that although PAF alone fails to elicit an oxidative burst in PMN, this lipid mediator was capable of amplifying the oxygen use by cells which were subsequently stimulated with FMLP (Ingraham et aJ. 1982) , and others have made similar observations (Dewald & Baggiolini. 1985) . In this paper we report results of an investigation on the in vitro and in vivo effects of sequential stimulation of PMN by first PAF and then FMLP.
MATERIALS AND METHODS
Cell preparation. PMN from heparinized venous blood were sedimented through cushions of Ficoll (Bsyum, 1968) Chemicals. Synthetic PAP, designated L-a-lecithin-j-acetyly-0-akyl, and its lyso derivative were obtained from Calbiochem-Behring Corp. (La Jolla, Calif.) . The PAF preparation which was 98% pure was that of Do & Ramachandran (1980) from chicken egg yolk. The alkyl groups are predominantly hexadecyl and octadecyl species. Preparation and storage of PAF stock solutions was as previously described (Ingraham et al, 1982) . Other phospholipids used were obtained from Applied Science (State College, Penn.). Cytochrome c (Type VI). bovine serum albumin (BSA), superoxide dismutase, FMLP, nordihydroguaiaretic acid (NDGA), and enzyme substrates were obtained from Sigma Chemical Co. (St Louis, Mo.) .
Measurements of 0; ion and released enzymes. Superoxide ion was measured as previously described (Ingraham et al, 1982) . Preliminary time course and dose response experiments revealed that PAF ( 10-g-10-8 M) treatment could be from 0 to 5 min before F h stimulation and produce enhanced effects. For enzyme release, 1-1.5 x lo7 PMN were incubated in 0.9 ml KRPG for 5 min at 37OC. PAP or its suspending medium was added and incubation continued an additional 5 min. FMLP was then added and incubation continued 2-5,5 or 10 min longer. At the end of the incubation the contents of the tube were centrifuged (400 8, 5 min, 4OC) and enzyme activities were determined on the cell-free supernatant. Beta glucuronidase, lysozyme and lactic acid dehydrogenase were determined by previously described methods (Ingraham et al, 1982) .
In vivo studies. For in vivo studies, stocks of PMLP were prepared by dissolving the peptide in 0.02 M sodium bicarbonate to a concentration of 1 mg/ml and diluted to final concentration in 1 ml of PBS.
White male New Zealand rabbits (2 f0.1 kg) were initially anaesthetized as previously described (Lash et al, 1983) . The anaesthesia was supplemented with inhalation ether during exposure of the femoral vessel. htramedic polyethylene tubing was used to catheterize the femoral artery and vein. Normal saline was administered via the venous line at a rate of 10 ml/h. A blood sample was drawn for the zero time value to leucocyte counts. Stimulant PAF (0.01 p g , i.e. 0.005 pg/ kg body weight) in a volume of 1 ml PBS with 0.2 5% BSA was administered via the venous line and blood samples were drawn from either the arterial or venous lines at 1 and 2.5 Aggregation. Procedure for aggregometry through use of a Payton, Model 300B aggregometer was as previously described (Ingraham et al, 1982) . Details are given in the legend of Fig 3. Statistics. Statistical significance was determined by t test comparing PAF-treated samples with controls incubated with 0.25% BSA in 0.9% NaCI. the suspending medium for PAF. For analysis of changes in leucocyte count during in vivo stimulation of rabbits, statistical significance of differences in slopes of curves during the recovery of AGC was determined by analysis of variance. ithsence of cytochalasin B. PAF has virtually no effect on 0; production (Ingraham ~t al, 1982) . Dose-response studies (Fig 1 ) showed that exposure to PAF concentrations as low as 1 0 -I ' M gave amplified responses with FMLP (10-8-10-b M). To determine if these effects were unique to PAF, we performed similar experiments with other phospholipids including phosphatidylethanolamine (PE), phosphatidylcholine (PC). lysophosphatidylcholine (LET) and the lyso derivative of PAF (LPAF). None of these compounds at M showed significant effects on enhancement of 0; production by PMN after exposure to Similar results were obtained when we examined the effects of treatment with PAF on FW-mediated release of lysozyme. Pretreatment with M PAF markedly increased the release when PMN were subsequently stimulated with M FMLP (Table II) . We cannot attribute the increase to PAF-promoted degranulation because, in the absence of cytochalasin B, PAF does not promote significant enzyme release (Ingraham et al, 1982) . P-Glucuronidase release from primary granules was negligible whether cells received pretreatment with PAF or not, suggesting that only the specific granules responded to this stimulation. As with 0; production, the other phospholipids (PE, PC, LPC and LPAF) at M had little effect on degranulation (data not shown).
RESULTS

ion production
Other workers (OFlaherty, 1985 : OFlaherty et al, 1981a , in examining effects of sequential stimulation by PAF and other stimuli on PMN functions, have results suggestive of a role for endproducts of lipoxygenase action on arachidonic acid. Accordingly, we examined the effect of NDGA, a lipoxygenase inhibitor, on PAF enhancement of FMLP responses. Neither lo-' M nor M NDGA diminished the enhancement effect of PAF on lysozyme release, however (Table 11 ).
M FMLP (Table I) . Fig  2) . Analysis of variance treatment of the slopes during the recovery phase, an approach which minimized day to day and animal to animal variability, revealed, however, that this phase was dramatically affected by PAF pretreatment. Granulocytopenia was sustained in the animals receiving both agents (Fig 2) . Analysis of variance of the regression lines for time points between 2.5 and 10 min post Fh4LP treatment showed that the difference was statistically significant 
Aggrega tion
One means by which granulocyte numbers in the peripheral circulation can be diminished is through aggregation of the cells to one another and their subsequent sequestration in the smaller capillaries. In view of the ampMed AGC response in rabbits receiving sequential doses of PAF and FMLP (Fig 2) (Snyderman & Goetzl, 1981; Goetzl& Pickett, 1980 Goetzl et al, 1980 . It is likely that the in vivo responses of PMN, however, are modulated by these agents acting in concert or in sequential fashion. Multiple stimulation of PMN has been studied in vitro. The approach most frequently employed has been to 'desensitize' PMN by an agent so that subsequent stimulation results in a diminished response. Upon repeated use of the same agent (i.e. homologous desensitization) PMN become refractory, often through 'down-regulation'. Decreased responsiveness has been demonstrated for repeated exposure of PMN to FMLP (Sullivan&Zigmond. 1980; Smith&Hollers, 1980) , as well as to CSa, to PAF, and to 5,12-dMEm (O'Flaherty et al, 198 1 b). Heterologous desensitization is also possible and may produce data suggestive of the sequence occurring in activation events. For example, pretreatment of PMN with certain agents produces diminished aggregation response to others. Exposure to PAF decreased the effect of subsequent stimulation by LTB4 (En et d, 1982) , while exposure to LTB4 diminished the responses to C5a, FMLP and PAF (O'Flaherty et al. 198 la) . Pretreatment with 5-hydroperoxyeicosatetraenoic acid induced chemotactic deactivation independent of the nature of the subsequent stimulus (Goetd et al,  1981) . Such results are consistent with a role for the arachidonic acid metabolites in stimulation by a variety of agents.
Stimulation with two different agents sequentially may also amplify response. We had earlier demonstrated that PAF and FMLP did not produce heterologous desensitization. Sequential exposure of chlorotetracycline-loaded PMN with combinations of PAF and FMLP showed that PAF treatment did not prohibit later FMLP responsiveness and vice versa (Ingraham et al, 1982 ). Furthermore, we had shown that PAF, which alone fails to elicit oxidative burst, was capable of amplifying the 0 2 use when P m were subsequently stimulated with FMLP. Dewald & Baggiolini (1985) have noted similar amplifying effects of PAF treatment on FMLP-induced superoxide ion generation. Similarly, platelets pretreated with PAF, while becoming refractory to subsequent PAF stimulation, had amplified response to other agents (Henson & Pinckard, 1977. see p. 17) .
Our present work, showing amplified superoxide production when cells are treated with PAF and then stimulated with FMLP, supports our prior observation showing enhanced oxygen utilization with a similar sequence of stimulation (Ingraham et al. 1982) . Because 0; production and O2 utilization are both expressions of the oxidative burst, it is expected that they would be affected in a similar fashion. We found also that degranulation is similarly afTected with PAF-treated cells showing from 1.2 to 2.5 times the release of lysozyme (Table II) . O'Flaherty (1985, p. 236 The enhancement effect appears to be particular to PAF as other phospholipids tested (PE, PC. LPC and WAF) at M do not cause significant enhancement (Table I ). The mechanism of PAF's effect on FMLP stimulation, however, is unknown. Fletcher & Gallin (1 980) were able to show that stimuli promoting degranulation caused an increase in the availability of FMLP receptor sites and a decrease in their binding atfinity. This effect was thought to be the result of granules fusing with the plasma membrane and thus expressing additional receptors associated with the granules. PAF might act by a different mechanism, however, because in the absence of cytocholasin B, at PAF concentrations as high as 5 x M there is no significant release of the granule enzymes (Ingraham et al, 1982) . PAF binding to PMN appears to occur through high affinity saturable speciAc sites as well as through non-saturable low atSnity sites (Valone & Goetd, 1983) . Either type of PAF binding might have localized effects which lead to alteration in af3nity or distribution of FMLP receptor sites on the plasma membrane. Alternatively, the specific binding of PAF might induce specific metabolic changes in the PMN which in turn heighten their ability to respond to FMLP. The possible arachidonic acid metabolites include 5-HETE and LTB4 (Borgeat & Samuelson, 1979; Goetzl& Sun. 1979) . The role of the former in PAF enhancement, however, is unclear since pretreatment with 5-HE2T itselfmay (Beckman et nl, 1985a) or may not (Beckman et d, 1985b; O'Flaherty et d. 1983) have enhancing effects on FMLP responses. On the other hand, LTB4 might have enhancing effects since pretreatment by this agent does promote 0; production by FMLPstimulatedPMN (Gayetal, 1984 : Dewald&Baggiolini, 1985 while at the same time it diminishes (i.e. desensitizes) PAFmediated aggregation (OFlaherty et al, 1981a) . PAF treatment of PMN itselfdoes result in enhanced production of LTB4 (Lin et Our studies on anaesthetized rabbits reveal that enhancing effects of PAF treatment on FMLP-mediated responses may be found not only in vitro but at least to some extent in the intact animal as well. Although we did not find significant differences in values of AGC at early times with and without PAF administration at 0.01 pg, prior PAF treatment did promote sustained granulocytopenia at times when AGC of animals receiving only FMLP showed return toward normal levels. Sequestration of granulocytes could be influenced by enhanced aggregation of the cells one to another and their subsequent trapping in the microvasculature. Our studies of FMLP-mediated aggregation in human cells indicates PAF treatment can enhance this in vitro response (Fig 3) . The effect had strict dependency on relative concentrations of PAF versus FMLP and could be observed only in the doseresponse regions in which the cells were neither significantly aggregating to the PAF treatment itself nor aggregating maximally to the FMLP stimulation.
Enhancement through sequential stimulation of Ph4N is not con6ned to treatment by PAF. Studies with PMN show that FMLP pretreatment heightens cell response to later stimulation by a variety of soluble (English et al, 1981) and particulate substances (Van Epps & Garcia, 1980) . Likewise, PMN treated with phorbol myristic acetate (PMA) followed by ionophore A231 8 7 produce enhanced arachidonic acid release (Volpi et d, 1985) . Further, sequential exposure of PMN to various combinations of the heterologous stimuli PMLP, A23 187 and PMA increases the amount of activated oxidase in membrane fractions (McPhall et d, 1984) . Thus, the interplay of various agents acting on PMN sequentially can profoundly influence responses. Enhancement of the oxidative responses through sequential stimulation might promote more effective management of microbial infection through greater production of microbicidal reduced oxygen by-products. Likewise, other increased PMN responses may widen the activities of these cells as they perform their role in host defence, 
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